Germline BRCA1 mutation detected in a multiple Endocrine neoplasia type 2 case with RET codon 634 mutation

B. Sarkadi, Kornélia Baghy, Z. Sápi, Gábor Nyirő, István Likó, A. Patócs

Research output: Contribution to journalArticle

Abstract

Coincidences of more than one pathogenic mutation in high and/or moderate risk-associated cancer genes have been rarely reported, and the implication for disease progression has been debated. We present a case harboring two autosomal dominant inherited mutations potentially aggravating the phenotype. Case report: A 16-year-old female was referred to the Endocrine Unit due to two palpable thyroid nodules and hair loss. Two hypoechoic, inhomogeneous masses with microcalcification in the thyroid gland were confirmed as medullary thyroid carcinoma. Genetic testing revealed a pathogenic heterozygous RET mutation associated with multiple endocrine neoplasia type 2 (MEN2). Furthermore, genetic screening identified the same mutation in the proband's clinically negative brother as well as in his two sons. The proband's mother and maternal aunt died of breast cancer. No samples were available from the deceased. The proband underwent further genetic counseling and BRCA1/2 testing. A novel, frameshift heterozygous BRCA1 mutation (BRCA1 p.Ile90Serfs, NC-000017.10:g.41256905-41256917) was identified in the proband, but it was absent in the brother and father, indicative of maternal inheritance. Breast or ovarian cancer was neither detected in our case at initial presentation nor during the 6-year follow-up. Conclusion: Coincidence of two monogenic autosomal dominant tumor syndromes is extremely rare, but it represents a significant therapeutic and cancer surveillance challenge. Due to the wider use of next generation sequencing in clinical practice, similar situations may occur more frequently.

Original languageEnglish
Article number544
JournalFrontiers in Genetics
Volume10
Issue numberJUN
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Multiple Endocrine Neoplasia Type 2a
Germ-Line Mutation
Codon
Mutation
Genetic Testing
Siblings
Mothers
Breast Neoplasms
Calcinosis
Thyroid Nodule
Neoplasm Genes
Alopecia
Genetic Counseling
Nuclear Family
Fathers
Ovarian Neoplasms
Disease Progression
Neoplasms
Thyroid Gland
Phenotype

Keywords

  • BRCA1 mutation
  • Cancer genetics
  • Medullary thyroid cancer
  • Multiple endocrine neoplasia type 2
  • RET mutation

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Genetics(clinical)

Cite this

Germline BRCA1 mutation detected in a multiple Endocrine neoplasia type 2 case with RET codon 634 mutation. / Sarkadi, B.; Baghy, Kornélia; Sápi, Z.; Nyirő, Gábor; Likó, István; Patócs, A.

In: Frontiers in Genetics, Vol. 10, No. JUN, 544, 01.01.2019.

Research output: Contribution to journalArticle

@article{c3f11dae36e54bfabfaf106bc355cdf6,
title = "Germline BRCA1 mutation detected in a multiple Endocrine neoplasia type 2 case with RET codon 634 mutation",
abstract = "Coincidences of more than one pathogenic mutation in high and/or moderate risk-associated cancer genes have been rarely reported, and the implication for disease progression has been debated. We present a case harboring two autosomal dominant inherited mutations potentially aggravating the phenotype. Case report: A 16-year-old female was referred to the Endocrine Unit due to two palpable thyroid nodules and hair loss. Two hypoechoic, inhomogeneous masses with microcalcification in the thyroid gland were confirmed as medullary thyroid carcinoma. Genetic testing revealed a pathogenic heterozygous RET mutation associated with multiple endocrine neoplasia type 2 (MEN2). Furthermore, genetic screening identified the same mutation in the proband's clinically negative brother as well as in his two sons. The proband's mother and maternal aunt died of breast cancer. No samples were available from the deceased. The proband underwent further genetic counseling and BRCA1/2 testing. A novel, frameshift heterozygous BRCA1 mutation (BRCA1 p.Ile90Serfs, NC-000017.10:g.41256905-41256917) was identified in the proband, but it was absent in the brother and father, indicative of maternal inheritance. Breast or ovarian cancer was neither detected in our case at initial presentation nor during the 6-year follow-up. Conclusion: Coincidence of two monogenic autosomal dominant tumor syndromes is extremely rare, but it represents a significant therapeutic and cancer surveillance challenge. Due to the wider use of next generation sequencing in clinical practice, similar situations may occur more frequently.",
keywords = "BRCA1 mutation, Cancer genetics, Medullary thyroid cancer, Multiple endocrine neoplasia type 2, RET mutation",
author = "B. Sarkadi and Korn{\'e}lia Baghy and Z. S{\'a}pi and G{\'a}bor Nyirő and Istv{\'a}n Lik{\'o} and A. Pat{\'o}cs",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fgene.2019.00544",
language = "English",
volume = "10",
journal = "Frontiers in Genetics",
issn = "1664-8021",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - Germline BRCA1 mutation detected in a multiple Endocrine neoplasia type 2 case with RET codon 634 mutation

AU - Sarkadi, B.

AU - Baghy, Kornélia

AU - Sápi, Z.

AU - Nyirő, Gábor

AU - Likó, István

AU - Patócs, A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Coincidences of more than one pathogenic mutation in high and/or moderate risk-associated cancer genes have been rarely reported, and the implication for disease progression has been debated. We present a case harboring two autosomal dominant inherited mutations potentially aggravating the phenotype. Case report: A 16-year-old female was referred to the Endocrine Unit due to two palpable thyroid nodules and hair loss. Two hypoechoic, inhomogeneous masses with microcalcification in the thyroid gland were confirmed as medullary thyroid carcinoma. Genetic testing revealed a pathogenic heterozygous RET mutation associated with multiple endocrine neoplasia type 2 (MEN2). Furthermore, genetic screening identified the same mutation in the proband's clinically negative brother as well as in his two sons. The proband's mother and maternal aunt died of breast cancer. No samples were available from the deceased. The proband underwent further genetic counseling and BRCA1/2 testing. A novel, frameshift heterozygous BRCA1 mutation (BRCA1 p.Ile90Serfs, NC-000017.10:g.41256905-41256917) was identified in the proband, but it was absent in the brother and father, indicative of maternal inheritance. Breast or ovarian cancer was neither detected in our case at initial presentation nor during the 6-year follow-up. Conclusion: Coincidence of two monogenic autosomal dominant tumor syndromes is extremely rare, but it represents a significant therapeutic and cancer surveillance challenge. Due to the wider use of next generation sequencing in clinical practice, similar situations may occur more frequently.

AB - Coincidences of more than one pathogenic mutation in high and/or moderate risk-associated cancer genes have been rarely reported, and the implication for disease progression has been debated. We present a case harboring two autosomal dominant inherited mutations potentially aggravating the phenotype. Case report: A 16-year-old female was referred to the Endocrine Unit due to two palpable thyroid nodules and hair loss. Two hypoechoic, inhomogeneous masses with microcalcification in the thyroid gland were confirmed as medullary thyroid carcinoma. Genetic testing revealed a pathogenic heterozygous RET mutation associated with multiple endocrine neoplasia type 2 (MEN2). Furthermore, genetic screening identified the same mutation in the proband's clinically negative brother as well as in his two sons. The proband's mother and maternal aunt died of breast cancer. No samples were available from the deceased. The proband underwent further genetic counseling and BRCA1/2 testing. A novel, frameshift heterozygous BRCA1 mutation (BRCA1 p.Ile90Serfs, NC-000017.10:g.41256905-41256917) was identified in the proband, but it was absent in the brother and father, indicative of maternal inheritance. Breast or ovarian cancer was neither detected in our case at initial presentation nor during the 6-year follow-up. Conclusion: Coincidence of two monogenic autosomal dominant tumor syndromes is extremely rare, but it represents a significant therapeutic and cancer surveillance challenge. Due to the wider use of next generation sequencing in clinical practice, similar situations may occur more frequently.

KW - BRCA1 mutation

KW - Cancer genetics

KW - Medullary thyroid cancer

KW - Multiple endocrine neoplasia type 2

KW - RET mutation

UR - http://www.scopus.com/inward/record.url?scp=85068995285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068995285&partnerID=8YFLogxK

U2 - 10.3389/fgene.2019.00544

DO - 10.3389/fgene.2019.00544

M3 - Article

AN - SCOPUS:85068995285

VL - 10

JO - Frontiers in Genetics

JF - Frontiers in Genetics

SN - 1664-8021

IS - JUN

M1 - 544

ER -